ICAD - Wutah bathi EPS kuartalan iCAD

Cloud-based AI diagnostic delivery accelerates diagnosis times, driving interest in the asset. The shift in the quarterly EPS level visualizes this trend, where the value 33.30 reflects the current magnitude. iCAD, Inc. (ICAD) focuses on implementing automated mammography screening for clinics, yet high R&D costs and a revenue deficit are depleting the company's cash reserves.

Earnings per share dynamics determine the long-term business valuation trend by filtering out short-term market noise. The percentage change in quarterly EPS measures net income growth rates relative to the previous period, reflecting the scaling efficiency of the iCAD, Inc. (ICAD) SaaS model in AI-powered breast cancer diagnostics and the impact of new B2B contracts on the final profitability of each share.